236 related articles for article (PubMed ID: 24697342)
1. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
Dumont C; Chenel M; Mentré F
J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
[TBL] [Abstract][Full Text] [Related]
2. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
[TBL] [Abstract][Full Text] [Related]
3. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.
Bazzoli C; Retout S; Mentré F
Stat Med; 2009 Jun; 28(14):1940-56. PubMed ID: 19266541
[TBL] [Abstract][Full Text] [Related]
4. Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.
Bazzoli C; Retout S; Mentré F
Comput Methods Programs Biomed; 2010 Apr; 98(1):55-65. PubMed ID: 19892427
[TBL] [Abstract][Full Text] [Related]
5. Comparison of robust criteria for D-optimal designs.
Foo LK; McGree J; Eccleston J; Duffull S
J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
[TBL] [Abstract][Full Text] [Related]
6. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
Nguyen TT; Bazzoli C; Mentré F
Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
[TBL] [Abstract][Full Text] [Related]
7. Methods of robust design of nonlinear models with an application to pharmacokinetics.
Foo LK; Duffull S
J Biopharm Stat; 2010 Jul; 20(4):886-902. PubMed ID: 20496212
[TBL] [Abstract][Full Text] [Related]
8. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
9. The bayesian bias correction method of the first-order approximation of nonlinear mixed-effects models for population pharmacokinetics.
Funatogawa T; Funatogawa I
J Biopharm Stat; 2007; 17(3):381-92. PubMed ID: 17479388
[TBL] [Abstract][Full Text] [Related]
10. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
Retout S; Comets E; Samson A; Mentré F
Stat Med; 2007 Dec; 26(28):5162-79. PubMed ID: 17486667
[TBL] [Abstract][Full Text] [Related]
11. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
Retout S; Mentré F; Bruno R
Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
[TBL] [Abstract][Full Text] [Related]
12. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.
Retout S; Mentré F
J Biopharm Stat; 2003 May; 13(2):209-27. PubMed ID: 12729390
[TBL] [Abstract][Full Text] [Related]
13. A pragmatic approach to the design of population pharmacokinetic studies.
Roy A; Ette EI
AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
[TBL] [Abstract][Full Text] [Related]
14. Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.
Lestini G; Dumont C; Mentré F
Pharm Res; 2015 Oct; 32(10):3159-69. PubMed ID: 26123680
[TBL] [Abstract][Full Text] [Related]
15. Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment.
Sjögren E; Nyberg J; Magnusson MO; Lennernäs H; Hooker A; Bredberg U
Drug Metab Dispos; 2011 May; 39(5):858-63. PubMed ID: 21289074
[TBL] [Abstract][Full Text] [Related]
16. A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.
Vajjah P; Duffull SB
Pharm Stat; 2012; 11(6):503-10. PubMed ID: 23059829
[TBL] [Abstract][Full Text] [Related]
17. Failed Pediatric Drug Development Trials.
Momper JD; Mulugeta Y; Burckart GJ
Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
[TBL] [Abstract][Full Text] [Related]
18. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
Foo LK; McGree J; Duffull S
Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
[TBL] [Abstract][Full Text] [Related]
19. Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.
Nyberg J; Bazzoli C; Ogungbenro K; Aliev A; Leonov S; Duffull S; Hooker AC; Mentré F
Br J Clin Pharmacol; 2015 Jan; 79(1):6-17. PubMed ID: 24548174
[TBL] [Abstract][Full Text] [Related]
20. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.
Steimer JL; Mallet A; Golmard JL; Boisvieux JF
Drug Metab Rev; 1984; 15(1-2):265-92. PubMed ID: 6745083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
